End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia

Shamia Hoque  
*University of South Carolina - Columbia*

Brian J. Chen  
*University of South Carolina - Columbia*

Martin W. Schoen  
*Saint Louis University*

Kenneth R. Carson  
*Washington University School of Medicine in St. Louis*

Jesse Keller  
*Washington University School of Medicine in St. Louis*

*See next page for additional authors*  
Follow this and additional works at: [https://digitalcommons.wustl.edu/open_access_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

**Recommended Citation**  
Hoque, Shamia; Chen, Brian J.; Schoen, Martin W.; Carson, Kenneth R.; Keller, Jesse; Witherspoon, Bartlett J.; Knopf, Kevin B.; Yang, Y Tony; Schooley, Benjamin; Nabhan, Chadi; Sartor, Oliver; Yarnold, Paul R.; Ray, Paul; Bobolts, Laura; Hrushesky, William J.; Dickson, Michael; and Bennett, Charles L., "End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia." PLoS One., . (2020).  
https://digitalcommons.wustl.edu/open_access_pubs/9254
Authors
Shamia Hoque, Brian J. Chen, Martin W. Schoen, Kenneth R. Carson, Jesse Keller, Bartlett J. Witherspoon, Kevin B. Knopf, Y Tony Yang, Benjamin Schooley, Chadi Nabhan, Oliver Sartor, Paul R. Yarnold, Paul Ray, Laura Bobolts, William J. Hrushesky, Michael Dickson, and Charles L. Bennett

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/9254
End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia

Shamia Hoque 1,2,*, Brian J. Chen 2,∗, Martin W. Schoen 3, Kenneth R. Carson 4, Jesse Keller 4, Bartlett J. Witherspoon 5, Kevin B. Knopf 6, Y. Tony Yang 7, Benjamin Schooley 8, Chadi Nabhan 9, Oliver Sarto 9, Paul R. Yarnold 5,6, Paul Ray 6, Laura Bobolts 10,11, William J. Hrushesky 5,6, Michael Dickson 10, Charles L. Bennett 9

1 Department of Civil and Environmental Engineering, College of Engineering and Computing, University of South Carolina, Columbia, South Carolina, United States of America, 2 Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, United States of America, 3 Department of Medicine, Saint Louis University School of Medicine, Saint Louis, Missouri, United States of America, 4 The Washington University School of Medicine and the Saint Louis VA Medical Center, St. Louis, Missouri, United States of America, 5 Medical University of South Carolina, Charleston, South Carolina, United States of America, 6 College of Pharmacy, University of South Carolina, Columbia, South Carolina, United States of America, 7 George Washington University, Washington, DC, United States of America, 8 Department of Integrated Information Technology, College of Engineering and Computing, University of South Carolina, Columbia, South Carolina, United States of America, 9 Tulane University School of Medicine, New Orleans, Louisiana, United States of America, 10 Oncology Analytics, Plantation, Florida, United States of America, 11 College of Pharmacy, Nova Southeastern University, Fort Lauderdale, Florida, United States of America

‡ These authors share first authorship on this work.

* hoques@cec.sc.edu

Abstract

Erythropoiesis stimulating agent (ESA) use was addressed in Food and Drug Administration (FDA) Oncology Drug Advisory Committee (ODAC) meetings between 2004 and 2008. FDA safety-focused regulatory actions occurred in 2007 and 2008. In 2007, black box warnings advised of early death and venous thromboembolism (VTE) risks with ESAs in oncology. In 2010, a Risk Evaluation Strategies (REMS) was initiated, with cancer patient consent that mortality and VTE risks were noted with ESAs. We report warnings and REMS impacts on ESA utilization among Veterans Administration (VA) cancer patients with chemotherapy-induced anemia (CIA). Data were from Veterans Affairs database (2003–2012). Epoetin and darbepoetin use were primary outcomes. Segmented linear regression was used to estimate changes in ESA use levels and trends, clinical appropriateness, and adverse events (VTEs) among chemotherapy-treated cancer patients. To estimate changes in level of drug prescription rate after policy actions, model-specific indicator variables as covariates based on specific actions were included. ESA use fell by 95% and 90% from 2005, for epoetin and darbepoetin, from 22% and 11%, respectively, to 1% and 1%, respectively, among cancer patients with CIA, respectively (p<0.01). Following REMS in 2010, mean hematocrit levels at ESA initiation decreased from 30% to 21% (p<0.01). Black box warnings preceded decreased ESA use among VA cancer patients with CIA. REMS was followed by reduced hematocrit levels at ESA initiation. Our findings contrast with privately-insured and Medicaid
insured cancer patient data on chemotherapy-induced anemia where ESA use decreased to 3% to 7% by 2010–2012. By 2012, the era of ESA administration to VA to cancer patients had ended but the warnings remain relevant and significant. In 2019, oncology/hematology national guidelines (ASCO/ASH) recommend that cancer patients with chemotherapy-induced anemia should receive ESAs or red blood cell transfusions after risk-benefit evaluation.

Introduction

Prescription drugs treat diseases and improve patients’ quality of life. However, no drug is completely safe [1,2]. Food and Drug Administration (FDA) balances risks and benefits by mandating manufacturer disclosure via warnings on product labels. Since 2007, FDA started requiring manufacturers to implement safety efforts, including consent via Risk Evaluation and Monitoring Strategies (REMS) [3–7]. A meta-analysis that public health advisories often led to decreased drug use and fleeting increases in drug monitoring [8]. No analyses report on use changes following REMS-mandated consent processes. Public health advisories impact incident, but not prevalent use [9,10]. Boxed warnings are associated with utilization reductions, but substitution between classes occurs [11–17]. Empirical evidence shows that boxed warnings have mixed results in leading to lower drug utilization. There is a need to identify factors associated with “rapid and sustained responses to risk communications.” [8]

We assessed impacts of boxed warnings and REMS on use and adverse outcomes of two drugs (epoetin and darbepoetin)- Erythropoiesis Stimulating Agents (ESAs). These drugs are associated with mortality and venous thromboembolism (VTE) risks when administered to cancer patients [18–28]. ESAs are approved for chemotherapy-induced anemias (CIAs) to minimize transfusions [18]. Meta-analytic studies found elevated thrombosis risk (7.5% vs. 4.9%) [19], increased mortality risk (Hazard Ratio = 1.10, 95% CI [1.01, 1.20]) [19] and Hazard Ratio = 1.17, 95% CI [1.06, 1.3]) [20] and decreased overall survival when cancer patients received ESAs (Hazard Ratio = 1.06, 95% CI [1.0, 1.12]) [20].

Discovery of adverse events led to boxed warnings in 2007 limiting ESA use to cancer patients with CIA receiving chemotherapy with palliative intent. FDA, concerned that label changes were insufficient, mandated in 2010 that ESAs have Risk Evaluation and Mitigation Strategies (REMS) [29,30]. REMS, enhanced regulatory actions [31], included medication guides; communication plans, elements to assure safe use, and plans for monitoring compliance [32].

ESA risk communication chronologies offers opportunities to study safety warnings in diverse settings as shown in Table 1. Past research in non-VA systems found ESA warnings had limited impact [8,20,33–42]. Distinctions between VA and non-VA systems exist [43]. In non-VA settings, drug companies rebate physician offices for administered intravenous drugs [44]. Differences between insurers’ reimbursed prices of intravenously infused biologics and physicians’ rebated prices represents incentives to prescribe drugs [44–46]. For VA physicians, financial incentives are lacking. We studied ESAs epoetin and darbepoetin separately, an important distinction [47] because price mark-ups, reimbursement policies, and intensity of pharmaceutical detailing differ between ESAs.

Changing prescribing behavior is essential. Little evidence evaluates warning effectiveness and FDA-mandated REMS in reducing serious adverse events [48–51]. Impacts of warnings
and REMS on utilization of ESAs and on adverse outcomes were assessed. Prescribing changes are particularly important in the setting of ESAs, where 2019 guidelines from the American Society of Clinical Oncology/the American Society of Hematology state that “depending on clinical circumstances, ESAs may be offered to patients with chemotherapy-associated anemia whose cancer treatment is not curative in intent and whose hemoglobin has declined to $< 10$ grams/deciliter [55]. Patterns of care data from South Carolina Medicaid showed that in 2010, 3% and 7% of cancer patients with chemotherapy-induced anemia received epoetin and darbepoetin, respectively [47]. It is not known what the frequency of use of epoetin and darbepoetin in the Veterans Administration system was in 2010—an observation that would have implications for current practice. In particular, if epoetin and darbepoetin use in 2010 in the VA setting were negligible, then this would imply that in the VA setting, clinicians strongly viewed red blood cell transfusion or allowing patients to have lower baseline hemoglobin levels as preferred to administered epoetin or darbepoetin for treatment of chemotherapy-induced anemia.

### Methods

#### Data

Data were from VA Integrated Service Networks (VISNs), using the VINCI (VA informatics and computing infrastructure) research environment. The Veterans Affairs Central Cancer Registry (VACCR) includes information on cancer diagnosis date, cancer site, stage of disease, and age, gender, race and ethnicity. VA Pharmacy Benefits files included national drug codes (NDC), prescription date, quantity, VA station number, and physician ID numbers. All of the patient information was anonymized during the data analysis stage. The study was reviewed by the full Institutional Review Board of the WJB Dorn Veterans Administration Medical Center (IRBNet Number: 1007797). The IRB waived the requirement of informed consent.

**Eligible chemotherapy-treated cancer patient identification.** Non-small cell lung cancer, colorectal cancers, and breast cancer were focused on. These cancers differ from each other in patient profiles, clinical characteristics, treatment, and prognoses. All patients had a diagnosis of cancer between 2005 and 2012. Eligible patients were at least 18 years old and younger than 90 years of age. Patients were tracked from chemotherapy administration for as long as chemotherapy was continually administered or death.

**Chemotherapy administration.** Chemotherapy administration was determined from inpatient/outpatient encounter records, pharmacy records, carrier claims and registry data between the date of the diagnosis (for registry cases) or first cancer claim (other cases) and six months later.
Outcomes

**ESA treatment use and transfusion.** For each course of chemotherapy administration, it was determined whether either epoetin or darbepoetin was dispensed. Use of ESA (epoetin, NDC (national drug code) 55513-126-xx and darbepoetin NDC code 55513-021-xx) was ascertained. Blood transfusion was identified from outpatient encounter data (CPT code 36430–36460).

**VTE occurrence and mortality.** A VTE event required an ICD-9 code in the first or second position on claims related files (the first claim), as per the method of Hershman et al in evaluating ESAs in the SEER-Medicare dataset [52]. For each chemotherapy course, the last epoetin or darbepoetin administration was identified and created an indicator variable equal to 1 for those with a VTE within 60 days after last ESA administration. Two indicators, vte60epo and vte60darbe, were created. If a patient died within courses of chemotherapy administration, an event observable based on date of death in vital statistics files, an indicator variable “died” was created equal to 1.

**Chronic conditions, hematocrit and cancer stage.** Comorbid disease was based on the Klabunde adaptation of Charlson indices [53]. Medicare inpatient/outpatient codes were searched for ICD-9 diagnostic codes and chronic conditions files. Each condition was weighted. Patients were assigned scores based on the Klabunde-Charlson index given comorbid conditions during chemotherapy administration periods. Hematocrit values were measured as percentages based on the average hematocrit values for three-months prior to ESA initiation. Cancer stage was designated as the closest in time prior to ESA initiation.

Control variables

**Sociodemographics.** Patient sociodemographic information included age, gender, race/ethnicity, and marital status. Age was measured from date of birth to date of cancer diagnosis or first claim for cancer. Age was categorized into five-year intervals. Race/ethnicity was categorized as African American, Hispanic, non-Hispanic white, and all others. Patients were identified as married/not.

**Geographic variables.** All data sets except SEER-Medicare provided patient residence at zip code levels. To ensure consistency, the geographic variable was defined at the county level.

**VA station ID variables.** These variables served as fixed effects in segmented regression analyses. These fixed effects absorb time-invariant unobserved characteristics in our longitudinal dataset, such as organizational incentives to prescribe drugs.

Statistical analyses: Segmented regression analyses

We used segmented linear regression to estimate changes in ESA use changes on levels and trends, clinical appropriateness, and adverse events (VTEs) among chemotherapy-treated cancer patients. The analysis was conducted separately for epoetin only, darbepoetin only, and for both epoetin/darbepoetin. These analyses accounted for baseline level and drug use trends while estimating changes in level and trend resulting from policy interventions. The models included a variable reflecting the number of intervals after the first quarter ($X_1(t)$). To estimate changes in level of drug prescription rate after policy actions, we included model-specific indicator variables as covariates based on specific actions were included.

We used slope and trend coefficients to help estimate mean differences between ESA rates of use between the intervention (the observed rate) and times without intervention (the expected rates) for specific quarters. The quarters were based on policy changes and other interventions of interest. The following quarters were evaluated: For ESAs, the first quarter after the FDA-disseminated public health advisories and the concomitant manufacturer-issued.
boxed warning on the ESA products (April to June 2007), the last quarter after the public health advisories and the box warnings and before initiation of the REMS program (October to December 2009), and the last quarter after REMS (October to December 2016). To assess model assumptions, we tested for residual autocorrelation at various lags. We used, partial autocorrelation and inverse autocorrelation plots to visually assess for residual autocorrelation. The regression had the following specification:

\[ y_{ijt} = \beta_0 + \beta_1 \cdot \text{counter}_t + \beta_2 \cdot \text{post boxed warning}_t + \beta_3 \cdot \text{quarters since boxed warning}_t + \beta_4 \cdot \text{post REMS}_t + \beta_5 \cdot \text{quarters since REMS}_t + \beta_6 \cdot X_{ijt} + \alpha_j + \epsilon_{ijt} \]

The subscript \(i\) denotes a unique patient, \(j\), a unique VA station, and \(t\), the time (in quarter) when chemotherapy began. \(Y\) is the various outcomes, including ESA use, adverse outcomes (VTE or death), control variables (i.e., Charlson index, hematocrit values, anemia diagnosis, and cancer stage). \(\text{Counter}\) is a variable that counted the number of quarters since the beginning study period (2005 quarter 1). It represented the slope of the trend in the outcome variable before any risk communications. \(\text{Post boxed warning}\) identified the level change in the outcome variable after warnings were announced in 2007 quarter 1. \(\text{Quarters since the public health advisories and the boxed warning}\) is a second counter variable that is 0 in all quarters prior to 2007 quarter 1 and begins counting at 1 through each passing quarter from 2007 quarter 1. The variable captured slope changes from pre-public health notifications and boxed warning periods to post-public health advisories and warning periods. Likewise, \(\text{post REMS}\) and \(\text{quarters since REMS}\) respectively captured the level change and the slope change (from the pre-REMS period) in outcome variables. \(X\), a vector of control variables, includes age, race, type of cancer, cancer stage, Charlson index, anemia diagnosis, and hematocrit. However, when one of these control variables was the dependent variable, it was removed as a control variable. Finally, \(\alpha\) (VA station fixed effects) controlled for time-invariant VA station-specific heterogeneity, and \(\epsilon\) was a random error term.

P-values for coefficient estimates for individual datasets and 95% confidence intervals are reported. All p-values were two-sided with a threshold of 0.05. All analyses were performed using Stata Version 15, with data assembly and cleaning in SQL and SAS.

**Results**

A total of 91,233 courses of chemotherapy administration was identified, some individuals received more than one chemotherapy course (Table 2). Only 8.5% of cancer patients with concomitant chemotherapy received at least one dose of epoetin, and the corresponding percentage for darbepoetin is 3.8%. At the height of ESA use, which occurred before the 2008 Warning, 23.2% and 11% of chemotherapy patients were respectively administered epoetin and darbepoetin (Figs 1 and 2).

In the overall sample, mean patient age was 67 years, of whom 6.5% were female. Our cohort is 64.9% White, and 12.3% African American. Lung cancer represented the largest percent at 59.2%, followed by colon cancer, and breast cancer at 25.4% and 5%. Patients had advanced cancer- 74.2% at stages 2, 3, and 4. Average Charlson index scores were 5.499, 24.2% of patients had anemia, and 5.5% of patients required blood transfusions. Overall, 28.6% of patients died.

Cancer patients administered chemotherapy and epoetin or darbepoetin were sicker than chemotherapy only populations, with greater proportions of cancer stages III or IV (49.4% and 51.1%), higher Charlson scores (6.31 and 6.32), greater anemia rates (65.9% and 63.1%) and transfusion (21.4% and 23.4%), and mortality rates (43.3% and 41.4%) respectively for epoetin and darbepoetin users. ESA use dropped after the Boxed Warning, but was falling even prior.
to this (Fig 1A and 1B). VTE rates and deaths did not inflect at the point of boxed warnings. Clinical indicators coincided with practices counseled by boxed warnings (Figs 3 and 4).

Multivariate regression analyses confirmed three trends: ESA use, both for epoetin and darbepoetin, fell consistently throughout the entire study period (2005–2012), with additional level changes occurring around the time of the boxed warnings; there is no evidence that the warnings reduced adverse events (VTEs and death); and following boxed warnings, VA physicians administered ESAs to patients with higher cancer stage. The most consistent results are that the boxed warnings were associated with most dramatic reductions in use of epoetin and darbepoetin (S1 Table). The negative coefficients on pre-Boxed Warning trends show that ESA use was already falling prior to the warnings. There were statistically significant discontinuities in ESA use, with reductions of 4.3% (p < 0.01) and 3.1% (p < 0.01) in likelihood of epoetin and darbepoetin prescription, respectively. Coefficients on changes in trend after the boxed warning, level changes after REMS, and trend changes after REMS are all positive and significant.

Because the cohort consists of all cancer patients on chemotherapy (S2 Table), the remaining regression results are interpreted as temporal trends in outcomes for VA cancer patients on chemotherapy. These results suggest no temporal changes in VTE or mortality risks. There was an increase of 3.7% in the likelihood of having an anemia diagnosis after REMS and increases in average Charlson scores by 0.16 (p < 0.01) and 0.32 (p < 0.01) after the boxed

### Table 2. Summary statistics.

|                          | All chemotherapy patients | Chemotherapy and epoetin | Chemotherapy and darbepoetin |
|--------------------------|---------------------------|--------------------------|------------------------------|
| N                        | 73,703                    | 7,051                    | 3,209                        |
| Age (years)              | 67.168 ± 10.076           | 66.828 ± 9.784           | 66.677 ± 9.740               |
| Female (%)               | 0.065 ± 0.049             | 0.049 ± 0.049            | 0.049 ± 0.049                |
| Married (%)              | 0.460 ± 0.490             | 0.490 ± 0.487            | 0.569 ± 0.487                |
| White (%)                | 0.649 ± 0.592             | 0.592 ± 0.569            | 0.161 ± 0.569                |
| Black (%)                | 0.123 ± 0.136             | 0.136 ± 0.161            | 0.161 ± 0.161                |
| Asian (%)                | 0.002 ± 0.001             | 0.001 ± 0.001            | 0.001 ± 0.001                |
| Hispanic (%)             | 0.008 ± 0.012             | 0.012 ± 0.004            | 0.004 ± 0.004                |
| Other race (%)           | 0.219 ± 0.259             | 0.259 ± 0.265            | 0.265 ± 0.265                |
| Epoetin (%)              | 0.085 ± 1.000             | 1.000 ± 1.000            | 1.000 ± 1.000                |
| Darbepoetin (%)          | 0.038 ± 0.451             | 1.000 ± 1.000            | 1.000 ± 1.000                |
| Chemotherapy (%)         | 1.000 ± 1.000             | 1.000 ± 1.000            | 1.000 ± 1.000                |
| Duration (months)        | 0.924 ± 1.413             | 0.390 ± 0.794            | 0.372 ± 0.757                |
| Lung cancer (%)          | 0.592 ± 0.664             | 0.664 ± 0.682            | 0.682 ± 0.682                |
| Breast cancer (%)        | 0.050 ± 0.028             | 0.028 ± 0.028            | 0.028 ± 0.028                |
| Colon cancer (%)         | 0.254 ± 0.171             | 0.171 ± 0.155            | 0.140 ± 0.155                |
| Lymphoma (%)             | 0.114 ± 0.143             | 0.143 ± 0.143            | 0.143 ± 0.143                |
| Cancer stage 1 (%)       | 0.258 ± 0.146             | 0.146 ± 0.138            | 0.138 ± 0.138                |
| Cancer stage 2 (%)       | 0.375 ± 0.360             | 0.360 ± 0.351            | 0.351 ± 0.351                |
| Cancer stages 3 & 4 (%)  | 0.367 ± 0.494             | 0.494 ± 0.511            | 0.511 ± 0.511                |
| Charlson Index           | 5.499 ± 6.306             | 6.306 ± 6.321            | 6.321 ± 6.314                |
| Anemia Diagnosis (%)     | 0.242 ± 0.659             | 0.659 ± 0.631            | 0.631 ± 0.631                |
| Transfusion (%)          | 0.055 ± 0.214             | 0.214 ± 0.234            | 0.234 ± 0.234                |
| Died (%)                 | 0.286 ± 0.433             | 0.433 ± 0.414            | 0.414 ± 0.414                |
| Hematocrit               | 36.883 ± 5.778            | 33.543 ± 5.484           | 33.560 ± 5.344               |

https://doi.org/10.1371/journal.pone.0234541.t002
Fig 1. (a) VA cancer patients on epoetin and (b) VA Cancer patients on darbepoetin.

https://doi.org/10.1371/journal.pone.0234541.g001
warning and REMS. The likelihood of being diagnosed as cancer stage 1 increased by 1.8% post Boxed Warning. S2 and S3 Tables focus on trends in outcome variables conditional respectively on epoetin and darbepoetin prescription, respectively. As in regressions using the entire cohort, our results show that neither mortality nor VTE rates fell over time. The most significant result is that hematocrit values at the time of ESA initiation dropped after REMS were initiated (p<0.01 for epoetin and darbepoetin).

**Discussion**

Our main findings are ESA use fell consistently throughout the study period, for both epoetin and darbepoetin, but the boxed warnings created an additional reduction in ESA utilization; adverse events (VTEs and death) did not decrease following boxed warnings or REMS; VA physicians responded differentially to the REMS versus the boxed warnings by decreasing the initial hematocrit level when initiating ESAs; and as of 2010, administration of epoetin or darbepoetin for treatment of chemotherapy-induced anemia was negligible.
Our results differ from literature where physicians are reimbursed for administering drugs intravenously in clinical settings. The divergence is interesting, given that all studies assess impacts of boxed warnings on the same drugs in different contexts—the VA system, Medicaid, Medicare, and commercial health insurance. Our results suggest that financial considerations do not appear to affect how VA physicians react to safety warnings.

In a prior study of the South Carolina Medicaid program where financial considerations are relevant, Noxon et al found differential utilization patterns for epoetin versus darbepoetin following warnings and safety actions [47]. For epoetin, utilization decreased steadily between 2002 and 2010, where darbepoetin use increased between 2003 and 2007 and then decreased thereafter. Per-patient dosing of darbepoetin, but not epoetin, increased between 2003 and 2010, and monthly per-patient epoetin costs decreased 3% while per-patients costs of darbepoetin increased 30% between 2003 and 2010. Noxon et al reported that in 2010, epoetin and darbepoetin were administer to 3% and 7%, respectively, or cancer patients with chemotherapy-induced anemia [54]. In contrast, in the VA system in 2010, 1% of cancer patients with

Fig 3. Percent of VA cancer patients with anemia diagnosis (a) epoetin, (b) darbepoetin, and average hematocrit levels of VA cancer patients (a) epoetin, (b) darbepoetin.

https://doi.org/10.1371/journal.pone.0234541.g003
Fig 4. Average cancer state of VA cancer patients for (a) epoetin and (b) darbepoetin.

https://doi.org/10.1371/journal.pone.0234541.g004
chemotherapy-induced anemia received epoetin or darbepoetin, respectively—strongly indicating the “end of the ESA era” at least in the VA system.

Among Medicare providers where financial considerations for individual providers are relevant, Bian et al showed that compared with a control group, ESA use started declining sharply after warnings were issued, concomitant with Center for Medicare and Medicaid Services (CMS) institution of a National Coverage Decision mandating non-payment for ESAs if hematocrit levels were > 30%, whereas ESA use trends remained similar with the control before warnings [55]. VTE trends were stable. The study found that the boxed warnings/CMS decision were associated with a 20.2-percentage-point reduction in likelihood of ESAs being used in the cancer setting, but were not associated with VTE reductions.

Our studycontradicts with results from a study by Schoen et al that uses the IMS LifeLink™ Health Plan Claims Database, which is composed of commercial health plan information [56]. They found that odds of receiving epoetin decreased after risk communications and REMS, but initially increased for darbepoetin after box warnings were disseminated. They found that the odds of receiving a high darbepoetin dose increased from 2001 to 2012, whereas odds of receiving a high epoetin dose decreased after REMS, suggesting that physicians increased per-patient darbepoetin dosing as the prevalence of darbepoetin use declined. Also, epoetin and darbepoetin rates of use in 2012 for chemotherapy-induced anemia were 3.1% and 2.6%, respectively, while in the VA, these rates of use were 1% and 1%, respectively.

Our study findings can be compared to those reported for Ontario, Canada for ESA use among cancer patients with chemotherapy-induced anemia between 2007 and 2009 and for VA use between 2002 and 2008 [57,58]. Tarlov et al and our study identifies the beginning of marked decrease in ESA use for chemotherapy-induced anemia beginning in 2005, following publications of poorer survival and high venous thromboembolism rates among ESA-treated cancer patients [57]. Their data is limited by not following ESA use beyond 2009 prior to initiating the ESA REMS program. Weir et al report that in Ontario, ESA use for chemotherapy induced anemia did not begin to decline until Canada Health and the FDA disseminated Black Box warnings about ESA use in these settings in 2007 [58]. In Canada, ESA use appeared to be influenced by national policies and regulatory decisions, whereas VA use of ESAs is strongly influenced by physician practice patterns, which changed markedly following publication of two large randomized controlled trials with ESAs in 2003.

While other incentive-driven contexts showed divergent utilization patterns between epoetin and darbepoetin, this was not seen herein. Yet ESA suppliers likely marketed their drugs with different degrees of aggressiveness. Amgen, the supplier of darbepoetin, settled civil litigation for allegations of over-promotion and over-marketing of darbepoetin (for $610 million to the Department of Justice and $72 million to 48 state Medicaid programs) and pled guilty to related criminal charges (paying $160 million—the largest federal fines/settlements in U.S. history related to a biologic product) [47]. VA physicians, who are paid a fixed salary, were less susceptible to pharmaceutical detailing.

**Conclusion**

ESA use fell in the VA system from 2005, even prior to the 2007 FDA boxed warnings for epoetin and darbepoetin, a finding that was initially reported by Tarlov et al. when evaluating VA use of ESAs between 2002 and 2009 [57]. Boxed warnings served as additional nudges to reduce utilization following safety-related concerns identified in clinical trials in 2003 and conform to clinical suggestions in warnings, such as to advise ESA use only among cancer patients treated for palliative intent. Possibly due in part to the low ESA use 2010, we did not find significant reductions in adverse outcomes because variance around these outcomes was great.
We also found that the mean hematocrit level decreased following the 2010 REMS—indicating that patient consent may have been associated with patient and physician reluctance to receive ESAs at higher hematocrit levels. Our results suggest that boxed warnings had intended effects in the VA, contrary to other insurance contexts where financial incentives to prescribe profitable injectable drugs may distort impacts of risk communications. REMS provided additional disincentives against ESA use that were not noted following the boxed warnings.

Taken in context with other studies by Bian et al. [55] for Medicare, Weir et al. [58] for Ontario, Canada, Noxon et al. [54] for South Carolina Medicaid, the results suggest that safety actions may have differential reactions across insurance types. ESA use appeared to have fallen earlier and was more consistent for epoetin and darbepoetin in the VA than in systems with financial incentives. This finding can help policymakers tailor messaging and supporting policies and/or regulatory action to specific insurance contexts. Policymakers may consider measures such as tort law changes (to raise “cost” of not heeding FDA risk communications), drug reimbursement policy reform and legislative reform on pharmaceutical marketing and detailing (to lower overprescribing), including a more nuanced interpretation of First Amendment free speech rights for off-label marketing.

A final important conclusion is that in the VA system, the era of administering epoetin or darbepoetin to cancer patients with chemotherapy-induced anemia appeared to end in 2012—a finding that is different from that reported among cancer patients covered by private health insurance or Medicaid health insurance.

Supporting information

S1 Table. Segmented regression analysis (all chemotherapy patients).
(DOCX)

S2 Table. Segmented regression analysis (epoetin).
(DOCX)

S3 Table. Segmented regression analysis (darbepoetin).
(DOCX)

Author Contributions

Conceptualization: Brian J. Chen, Kevin B. Knopf, Y. Tony Yang, Oliver Sartor, Paul R. Yarnold, William J. Hrushesky, Michael Dickson, Charles L. Bennett.

Formal analysis: Shamia Hoque, Brian J. Chen, Martin W. Schoen, Kevin B. Knopf, Benjamin Schooley, Paul R. Yarnold, William J. Hrushesky, Michael Dickson, Charles L. Bennett.

Funding acquisition: Brian J. Chen, Benjamin Schooley, Charles L. Bennett.

Investigation: Brian J. Chen, Kenneth R. Carson.

Methodology: Shamia Hoque, Brian J. Chen.

Writing – original draft: Brian J. Chen, Martin W. Schoen, Jesse Keller, Kevin B. Knopf, Benjamin Schooley, Chadi Nabhan, Paul R. Yarnold, Michael Dickson, Charles L. Bennett.

Writing – review & editing: Shamia Hoque, Brian J. Chen, Martin W. Schoen, Kenneth R. Carson, Jesse Keller, Bartlett J. Witherspoon, Kevin B. Knopf, Y. Tony Yang, Benjamin Schooley, Chadi Nabhan, Oliver Sartor, Paul R. Yarnold, Paul Ray, Laura Bobolts, William J. Hrushesky, Michael Dickson.

Writing - Review & Editing: Charles L. Bennett.
References

1. Lazarou JPBHC PN: Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA: The Journal of the American Medical Association 279:1200–1205, 1998

2. Food and Drug Administration: Preventable Adverse Drug Reactions: A Focus on Drug Interactions, available at http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm110632.htm, accessed September 19, 2014

3. Center for Drug Evaluation and Research: Guidance: Drug Safety Information—FDA's Communication to the Public, Food and Drug Administration, March, 2012

4. Goldfrank LR, Flomenbaum N, Lewin NA, et al: Goldfrank’s toxicologic emergencies, McGraw-Hill New York, 2002

5. Weaver J, Grenade LL, Kwon H, et al: Finding, evaluating, and managing drug-related risk approaches taken by the US Food and Drug Administration (FDA). Dermatologic therapy 22:204–215, 2009 https://doi.org/10.1111/j.1529-8019.2009.01233.x PMID: 19453344

6. Ehrenpreis ED, Ciocciola AA, Kulkarni PM: How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications. The American journal of gastroenterology 107:501–504, 2012 https://doi.org/10.1038/ajg.2011.449 PMID: 22745958

7. Qato DM, Alexander GC: Improving the Food and Drug Administration's Mandate to Ensure Postmarketing Drug Safety. JAMA: The Journal of the American Medical Association 306:1595–1596, 2011 https://doi.org/10.1001/jama.2011.1457 PMID: 21990303

8. Dusetzina SB, Higashi AS, Dorsey ER, et al: Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review. Medical care 50:466, 2012 https://doi.org/10.1097/MLR.0b013e318245a160 PMID: 22266704

9. Weatherby LB, Nordstrom BL, Fife D, et al: The impact of wording in “Dear doctor” letters and in black box labels. Clinical Pharmacology & Therapeutics 72:735–742, 2002

10. Weatherby LB, Walker AM, Fife D, et al: Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of ‘Dear Doctor’letters. Pharmacoepidemiology and drug safety 10:211–218, 2001 https://doi.org/10.1002/pds.592 PMID: 11501334

11. Libby AM, Orton HD, Valuck RJ: Persisting decline in depression treatment after FDA warnings. Archives of General Psychiatry 66:633–639, 2009 https://doi.org/10.1001/archgenspsychiatry.2009.46 PMID: 19487628

12. Nemeroff CB, Kalali A, Keller MB, et al: Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Archives of general psychiatry 64:466–472, 2007 https://doi.org/10.1001/archpsyc.64.4.466 PMID: 17404123

13. Kurian BT, Ray WA, Arbogast PG, et al: Effect of regulatory warnings on antidepressant prescribing for children and adolescents. Archives of pediatrics & adolescent medicine 161:690–696, 2007

14. Valuck RJ, Libby AM, Orton HD, et al: Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 164:1198–205, 2007 https://doi.org/10.1176/appi.ajp.2007.07010007 PMID: 17671282

15. Valuck RJ, Libby AM, Orton HD, et al: Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs. American Journal of Psychiatry 164:1198–1205, 2007 https://doi.org/10.1176/appi.ajp.2007.07010007 PMID: 17671282

16. Kessler TL, Harrison DL, Hagemann TM: Promethazine prescribing patterns in pediatric inpatients younger than two years before and after the product black box warning. Hospital Pharmacy 45:389–392, 2010

17. Bowen ME, Ray WA, Arbogast PG, et al: Increasing exposure to angiotensin-converting enzyme inhibitors in pregnancy. American journal of obstetrics and gynecology 198:291. e1-291. e5, 2008 https://doi.org/10.1016/j.ajog.2007.09.009 PMID: 18191803

18. Bohlius J, Wilson J, Seidenfeld J, et al: Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. Journal of the National Cancer Institute 98:708–714, 2006 https://doi.org/10.1093/jnci/dj189 PMID: 16705125

19. Bennett CL, Silver SM, Djulbegovic B, et al: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA: The Journal of the American Medical Association 299:914–924, 2008

20. Bohlius J, Schmidlin K, Brilliant C, et al: Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. The Lancet 373:1532–1542, 2009

21. Henke M, Laszig R, Rübe C, et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. The Lancet 362:1255–1260, 2003
22. Leyland-Jones B, Semiglavzov V, Pawlicki M, et al: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. Journal of Clinical Oncology 23:5960–5972, 2005. https://doi.org/10.1200/JCO.2005.06.150 PMID: 16087945

23. Wright JR, Ung YC, Julian JA, et al: Randomized, double-blind, placebo-controlled trial of erythropoietin in non–small-cell lung cancer with disease-related anemia. Journal of Clinical Oncology 25:1027–1032, 2007. https://doi.org/10.1200/JCO.2006.07.1514 PMID: 17312332

24. Smith RE Jr, Aapro MS, Ludwig H, et al: Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Oncology 26:1040–1050, 2008. https://doi.org/10.1200/JCO.2007.14.2885 PMID: 18227526

25. Hedenus M, Adriasson M, Miguel JS, et al: Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. British journal of haematology 122:394–403, 2003. https://doi.org/10.1046/j.1365-2141.2003.04448.x PMID: 12877666

26. Overgaard J, Hoff C, Sand Hansen H, et al: 6LB Randomized study of the importance of Novel Erythropoiesis Stimulating Protein (Aranesp®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC)–the Danish Head and Neck Cancer Group DAHANCA 10 randomized trial. European Journal of Cancer Supplements 5:7, 2007.

27. Thomas G, Ali S, Hoebers FJP, et al: Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecologic oncology 108:317–325, 2008. https://doi.org/10.1016/j.ygyno.2007.10.011 PMID: 18037478

28. Rizzo JD, Somerfield MR, Hagerty KL, et al: Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. Journal of Clinical Oncology 26:132–149, 2008. https://doi.org/10.1200/JCO.2007.14.3396 PMID: 17954713

29. Reeves DJ, Quebe AK, Patel R: The ESA APPRISE Oncology Program: A History of REMS Requirements, a Review of the Data, And an Approach to Compliance in the Hospital. Pharmacy and Therapeutics 36:423, 2011 PMID: 21931474

30. ESA APPRISE Oncology Program: What is the ESA APPRISE Oncology Program?, 2011.

31. Wright JR, Ung YC, Julian JA, et al: Randomized, double-blind, placebo-controlled trial of erythropoietin in non–small-cell lung cancer with disease-related anemia. J Clin Oncol 25:1027–32, 2007. https://doi.org/10.1200/JCO.2006.07.1514 PMID: 17312332

32. Faden LB, Milne CP: Pharmacovigilance activities in the United States, European Union and Japan: harmonic convergence or convergent evolution. Food & Drug LJ 63:683, 2008.

33. Bohlius J, Wilson J, Seidenfeld J, et al: Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 3, 2006.

34. Dorsey E, Rabbani A, Gallagher SA, et al: Impact of FDA black box advisory on antipsychotic medication use. Archives of Internal Medicine 170:96, 2010. https://doi.org/10.1001/archinternmed.2009.456 PMID: 20665205

35. Valluri S, Zito JM, Safer DJ, et al: Impact of the 2004 Food and Drug Administration pediatric suicidality warning on antidepressant and psychotherapy treatment for new-onset depression. Medical care 48:947, 2010. https://doi.org/10.1097/MLR.0b013e3181e9d2b PMID: 20856141

36. Lineberry TW, Bostwick JM, Beebe TJ, et al: Impact of the FDA black box warning on physician antidepressant prescribing and practice patterns: opening Pandora’s suicide box. Mayo Clinic Proceedings, Elsevier, 2007, pp 518–520. https://doi.org/10.4065/82.4.518 PMID: 17480319

37. Lu CY, Zhang F, Lakoma MD, et al: Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study. Bmj 348:g3596, 2014. https://doi.org/10.1136/bmj.g3596 PMID: 24942789

38. Wilkinson JJ, Force RW, Cady PS: Impact of safety warnings on drug utilization: marketplace life span of cisapride and troglitazone. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 24:978–986, 2004.

39. Piening S, Haaijer-Ruskamp FM, de Vries JT, et al: Impact of safety-related regulatory action on clinical practice. Drug safety 35:373–385, 2012. https://doi.org/10.2165/11599100-000000000-0000 PMID: 22400319

40. Desai VC, Heaton PC, Kelton CM: Impact of the Food and Drug Administration’s antipsychotic black box warning on psychotropic drug prescribing in elderly patients with dementia in outpatient and office-based settings. Alzheimer’s & Dementia 8:453–457, 2012.
41. Stewart KA, Natzke BM, Williams T, et al: Temporal trends in anti-diabetes drug use in tricare following safety warnings in 2007 about rosiglitazone. Pharmacoepidemiology and drug safety 18:1048–1052, 2009 https://doi.org/10.1002/peds.1819 PMID: 19655338
42. Goldman SA: Communication of Medical Product Risk. Drug Safety 27:519–534, 2004
43. Federal Anti—Kickback Statute, 1320a - 7(b)
44. Johnson C: This controversial rule could change how doctors profit from using the most expensive drugs, Washington Post, 2016
45. Whoriskey P: Anemia drug made billions, but at what cost?, Washington Post, 2012
46. Werbie C, Wilensky G, Goldstein D, et al: Prescription Drug Pricing: Medicare Part B. Health Affairs, 2017
47. Noxon V, Knopf KB, Norris LB, et al: Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia. Journal of Oncology Practice:JOP. 2016. 019364, 2017
48. American Medical Association: Reports of the Council on Science and Public Health, The Evolving Culture of Drug Safety in the United States: Risk Evaluation and Mitigation Strategies (REMS), In Health RotCoSaP (ed): 2010 Annual Meeting, 2010, pp 402
49. Wilson A, Milne CP: FDA’s Risk Evaluation and Mitigation Strategies (REMS): Effective and Efficient Safety Tools or Process Poltergeist. Food & Drug LJ 66:569, 2011
50. Baker DE: Editorial-REMS—One Year Later. Hospital Pharmacy 45:348–351, 2010
51. Singh AK: Message to the FDA on ESAs: REMS is not enough, more studies are needed. Clinical Journal of the American Society of Nephrology 5:1355–1358, 2010 https://doi.org/10.2215/CJN.03560410 PMID: 20688885
52. Hershman DL, Buono DL, Malin J, et al: Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. JNCI: Journal of the National Cancer Institute 101:1633–1641, 2009 https://doi.org/10.1093/jnci/djp387 PMID: 19903808
53. Klabunde CN, Potosky AL, Legler JM, et al: Development of a comorbidity index using physician claims data. Journal of clinical epidemiology 53:1258–1267, 2000 https://doi.org/10.1016/s0895-4356(00)00256-0 PMID: 11146273
54. Noxon V, Knopf KB, Norris LB, et al: Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia. J Oncol Pract 13:e562–e573, 2017 https://doi.org/10.1200/JOP.2016.019364 PMID: 28504901
55. Bian J, Chen B, Hershman DL, et al: Effects of the US Food and Drug Administration Boxed Warning of Erythropoetin-Stimulating Agents on Utilization and Adverse Outcome. Journal of Clinical Oncology 35:1945–1951, 2017 https://doi.org/10.1200/JCO.2017.72.6273 PMID: 28441110
56. Schoen MW, Hoque S, Witherspoon BJ, et al: End of an era for erythropoiesis-stimulating agents in oncology. International Journal of Cancer 146:2829–2835, 2020 https://doi.org/10.1002/jc.32917 PMID: 32037527
57. Tarlov E, Stroupe KT, Lee TA, et al: Trends in anemia management in lung and colon cancer patients in the US Department of Veterans Affairs, 2002–2008. Support Care Cancer 20:1649–57, 2012 https://doi.org/10.1007/s00520-011-1255-0 PMID: 21935718
58. Weir MA, Gomes T, Winqvist E, et al: Effects of funding policy changes and health warnings on the use of erythropoiesis-stimulating agents. J Oncol Pract 8:179–83, 2012 https://doi.org/10.1200/JOP.2011.00287 PMID: 22942813